SCHEMBL430682

SCHEMBL430682

C=C1CC(C)(C)Cc2ccc(Br)cc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP1 P53582 1/20 0.42
PDE4B Q07343 1/20 0.36
CHEK2 O96017 1/20 0.36
ROS1 P08922 1/20 0.36
MARK3 P27448 1/20 0.36
LTK P29376 1/20 0.36
FLT4 P35916 1/20 0.36
KDR P35968 1/20 0.36
MINK1 Q8N4C8 1/20 0.36
AURKB Q96GD4 1/20 0.36
PBK Q96KB5 1/20 0.36
STK17A Q9UEE5 1/20 0.36
MAP4K5 Q9Y4K4 1/20 0.36
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
TDP2 O95551 1/20 0.34
PARP1 P09874 1/20 0.34
PARP10 Q53GL7 1/20 0.34
PGR P06401 2/20 0.34
TGM2 P21980 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL427867 0.79 ALDH1A1 (0.44) METAP1TDP1L3MBTL1TDP2PARP1
SCHEMBL1794485 0.77 PNMT (0.40) METAP1TDP2PGRBRD4CMA1
SCHEMBL7724755 0.76 PDE4B (0.35) METAP1PDE4BCHEK2ROS1MARK3
SCHEMBL3362722 0.71 TDP1 (0.52) METAP1CHEK2ROS1MARK3LTK
SCHEMBL29914776 0.71 TDP1 (0.52) METAP1CHEK2ROS1MARK3LTK
SCHEMBL30676574 0.69 TDP1 (0.46) METAP1PDE4BCHEK2ROS1MARK3
SCHEMBL1572850 0.69 TDP1 (0.46) METAP1PDE4BCHEK2ROS1MARK3
SCHEMBL30643139 0.68 METAP1 (0.46) METAP1CHEK2ROS1MARK3LTK
SCHEMBL6209711 0.68 METAP1 (0.46) METAP1CHEK2ROS1MARK3LTK
SCHEMBL13950513 0.68 TDP2 (0.45) METAP1TDP1TDP2PARP10BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065195-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES ARRAY BIOPHARMA INC. 2012-03-15 US disclosed
US-20120065195-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES ARRAY BIOPHARMA INC. 2012-03-15 US disclosed
US-20120065195-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES ARRAY BIOPHARMA INC. 2012-03-15 US disclosed
WO-2011123674-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES ARRAY BIOPHARMA INC. (US) 2011-10-06 WO disclosed
WO-2011123674-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES ARRAY BIOPHARMA INC. (US) 2011-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065195-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES APP, BACE1, PSEN1 METAP1 630/4885PDE4B 789/4885CHEK2 3941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.